期刊
UROLOGY
卷 83, 期 3, 页码 664-669出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.urology.2013.10.026
关键词
-
资金
- Ferring
- Janssen
- NCI
- Dendreon
- Sanofi
- Progenics
- Lilly
- OncoGeneX
- Rogosin Institute
- Astex Pharmaceuticals
Prostate cancer is often associated with metastases to bone and/or soft tissue. The progression to metastatic castrate-resistant prostate cancer is a seminal event in disease progression affecting treatment decisions. A multidisciplinary group was convened to review the currently available imaging guidelines for metastatic disease in prostate cancer and found no consensus on eligibility criteria, type of imaging modality, and the frequency of scanning for detecting metastatic disease. The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer. UROLOGY 83: 664-669, 2014. (C) 2014 Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据